Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz's Carol Lynch Highlights Decade Of Biosimilar Dominance And Plans For Many More Winning Years

Executive Summary

2016 marks the 10 year anniversary of the first biosimilar approval in Europe, Sandoz Inc.'s Omnitrope (somatropin), but only the first anniversary for approval of a biologic copycat drug in the US – a country that has been slow to embrace the concept. Sandoz's global head of biopharmaceuticals and oncology, Carol Lynch, explains to Scrip how the biosimilars market has developed over the last decade and what the biggest challenges have been along the way.

You may also be interested in...



Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.

Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing

Sandoz has used data extrapolation to all the indications for Roche's MabThera in its marketing submission for biosimilar rituximab, just accepted for review by the European Medicines Agency.

Court Probes Rationale Of Biosimilars' 180-Day Notice

There was a lot of inside baseball being played at the US Court of Appeals for the Federal Circuit during April 4 oral arguments when Amgen Inc. battled Apotex Inc. over whether Congress intended for it to be mandatory for biosimilar makers to provide 180 days notice of commercial marketing (NCM) to the reference product sponsor (RPS) after the FDA licenses a copycat product.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel